What is the treatment for IgA (Immunoglobulin A) vasculitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

The treatment for IgA vasculitis should be tailored to the severity of symptoms and organ involvement, with glucocorticoids being the first-line therapy for severe manifestations, especially in adults, as supported by the most recent study 1. The management of IgA vasculitis depends on the severity of symptoms, with mild cases often requiring only supportive care, while severe cases need more aggressive intervention.

  • For mild cases with minimal symptoms, treatment includes adequate hydration, rest, and over-the-counter pain relievers like acetaminophen or NSAIDs such as ibuprofen for joint pain and fever.
  • Patients with more severe symptoms may require corticosteroids, typically oral prednisone at 1-2 mg/kg/day for 1-2 weeks followed by a gradual taper over several weeks.
  • For severe cases with significant kidney involvement, high-dose pulse methylprednisolone (30 mg/kg/day for 3 days) may be used, followed by oral prednisone, as suggested by 2.
  • In cases with severe nephritis or other organ complications, immunosuppressive medications like cyclophosphamide, azathioprine, or mycophenolate mofetil might be added, with rituximab showing promise in reducing relapse frequency and achieving long-term remission, as noted in 1.
  • Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers may be prescribed to manage hypertension and protect kidney function, highlighting the importance of monitoring blood pressure, urinalysis, and kidney function during and after treatment, as kidney complications can develop weeks after initial symptoms appear, as discussed in 3 and 4. IgA vasculitis is caused by abnormal immune complex deposition in small blood vessels, which explains why immunosuppressive treatments are effective in controlling the inflammatory response, as explained in 5. The role of various immunomodulatory therapies, such as calcineurin inhibitors and mycophenolate mofetil, remains promising, while other potential therapies with encouraging results require further research, as concluded in 1.

References

Research

[Immunoglobulin A vasculitis (IgAV)].

Zeitschrift fur Rheumatologie, 2023

Research

IgA vasculitis.

Seminars in immunopathology, 2021

Research

IgA Vasculitis in Adults: a Rare yet Challenging Disease.

Current rheumatology reports, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.